New York State Common Retirement Fund trimmed its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 51.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 237,939 shares of the company’s stock after selling 248,465 shares during the quarter. New York State Common Retirement Fund owned about 0.12% of TherapeuticsMD worth $1,254,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of TXMD. American International Group Inc. lifted its stake in shares of TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock worth $665,000 after buying an additional 6,103 shares during the last quarter. Teachers Advisors LLC lifted its stake in shares of TherapeuticsMD by 1.4% in the first quarter. Teachers Advisors LLC now owns 639,602 shares of the company’s stock worth $4,605,000 after buying an additional 9,077 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of TherapeuticsMD by 5.6% in the first quarter. Vanguard Group Inc. now owns 9,801,870 shares of the company’s stock worth $70,574,000 after buying an additional 515,992 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of TherapeuticsMD by 10.1% in the first quarter. Geode Capital Management LLC now owns 1,279,601 shares of the company’s stock worth $9,213,000 after buying an additional 117,660 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its stake in shares of TherapeuticsMD by 10.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 626,312 shares of the company’s stock worth $4,510,000 after buying an additional 60,229 shares during the last quarter. Institutional investors and hedge funds own 71.54% of the company’s stock.

Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) opened at 4.72 on Wednesday. The firm’s market capitalization is $963.01 million. TherapeuticsMD, Inc. has a 52 week low of $3.50 and a 52 week high of $8.30. The stock has a 50 day moving average of $4.86 and a 200-day moving average of $4.86.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative net margin of 485.71% and a negative return on equity of 74.25%. The business had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. During the same period last year, the business earned ($0.11) earnings per share. The firm’s revenue was down 3.4% on a year-over-year basis. Equities analysts anticipate that TherapeuticsMD, Inc. will post ($0.44) earnings per share for the current fiscal year.

TXMD has been the subject of a number of analyst reports. Deutsche Bank AG initiated coverage on shares of TherapeuticsMD in a research note on Friday, July 21st. They issued a “buy” rating and a $10.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research note on Monday, September 4th. CIBC upgraded shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 11th. Oppenheimer Holdings, Inc. upgraded shares of TherapeuticsMD from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research note on Tuesday, July 11th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research note on Friday, September 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $14.88.

ILLEGAL ACTIVITY NOTICE: “New York State Common Retirement Fund Sells 248,465 Shares of TherapeuticsMD, Inc. (TXMD)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://theolympiareport.com/2017/11/01/new-york-state-common-retirement-fund-sells-248465-shares-of-therapeuticsmd-inc-txmd.html.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction on Wednesday, August 30th. The stock was acquired at an average price of $5.99 per share, with a total value of $29,950.00. Following the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 23.92% of the stock is currently owned by company insiders.

TherapeuticsMD Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD, Inc. (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.